Tags

Type your tag names separated by a space and hit enter

Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study.
J Rheumatol 2016; 43(7):1335-9JR

Abstract

OBJECTIVE

To determine the incidence of systemic lupus erythematosus (SLE) and SLE with concomitant or subsequent lupus nephritis (LN) in Denmark during 1995-2011, using data from the Danish National Patient Registry (NPR).

METHODS

To assess the incidence of SLE, we identified all persons aged ≥ 18 years in the NPR with at least 1 International Classification of Diseases, 10th ed (ICD-10) code of SLE and at least 365 days of followup under this diagnosis. Identification of LN cases was based on fulfillment of these criteria and ≥ 1 registration under an ICD-10 code of nephritis concomitantly with or after first SLE registration.

RESULTS

The overall annual incidence rate per 100,000 for SLE was 2.35 (95% CI 2.24-2.49); 0.69 (95% CI 0.60-0.78) for men and 3.96 (95% CI 3.75-4.17) for women. For LN, the mean annual incidence rate per 100,000 was estimated to be 0.45 (95% CI 0.38-0.53); 0.20 (95% CI 0.13-0.28) for men and 0.69 (95% CI 0.57-0.83) for women. The differences in SLE incidence rates between sexes decreased by age, and the incidence did not differ between men and women after the age of 60 years for LN. The estimated incidences showed no trends by calendar time. Estimated overall point prevalence (December 31, 2011) per 100,000 was 45.2 (95% CI 43.3-47.4) and 6.4 (95% CI 5.7-7.2) for SLE and LN, respectively.

CONCLUSION

Our Danish population-based data showed a stable incidence of SLE and LN. As expected, we found higher incidence rates among women than among men, particularly in younger persons.

Authors+Show Affiliations

From the Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital, Copenhagen; Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.M.L. Hermansen, MD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; J. Lindhardsen, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, and Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital; C. Torp-Pedersen, MD, DMSc, Professor of Cardiology, Department of Health Science and Technology, Aalborg University; M. Faurschou, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; S. Jacobsen, MD, DMSc, Professor of Rheumatology, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet. Marie-Louise.From.Hermansen@regionh.dk.From the Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital, Copenhagen; Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.M.L. Hermansen, MD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; J. Lindhardsen, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, and Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital; C. Torp-Pedersen, MD, DMSc, Professor of Cardiology, Department of Health Science and Technology, Aalborg University; M. Faurschou, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; S. Jacobsen, MD, DMSc, Professor of Rheumatology, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet.From the Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital, Copenhagen; Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.M.L. Hermansen, MD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; J. Lindhardsen, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, and Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital; C. Torp-Pedersen, MD, DMSc, Professor of Cardiology, Department of Health Science and Technology, Aalborg University; M. Faurschou, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; S. Jacobsen, MD, DMSc, Professor of Rheumatology, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet.From the Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital, Copenhagen; Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.M.L. Hermansen, MD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; J. Lindhardsen, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, and Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital; C. Torp-Pedersen, MD, DMSc, Professor of Cardiology, Department of Health Science and Technology, Aalborg University; M. Faurschou, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; S. Jacobsen, MD, DMSc, Professor of Rheumatology, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet.From the Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital, Copenhagen; Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.M.L. Hermansen, MD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; J. Lindhardsen, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, and Department of Cardiology, Copenhagen University Hospital, Gentofte Hospital; C. Torp-Pedersen, MD, DMSc, Professor of Cardiology, Department of Health Science and Technology, Aalborg University; M. Faurschou, MD, PhD, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet; S. Jacobsen, MD, DMSc, Professor of Rheumatology, Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27134247

Citation

Hermansen, Marie-Louise F., et al. "Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: a Nationwide Cohort Study." The Journal of Rheumatology, vol. 43, no. 7, 2016, pp. 1335-9.
Hermansen ML, Lindhardsen J, Torp-Pedersen C, et al. Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study. J Rheumatol. 2016;43(7):1335-9.
Hermansen, M. L., Lindhardsen, J., Torp-Pedersen, C., Faurschou, M., & Jacobsen, S. (2016). Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study. The Journal of Rheumatology, 43(7), pp. 1335-9. doi:10.3899/jrheum.151221.
Hermansen ML, et al. Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: a Nationwide Cohort Study. J Rheumatol. 2016;43(7):1335-9. PubMed PMID: 27134247.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study. AU - Hermansen,Marie-Louise F, AU - Lindhardsen,Jesper, AU - Torp-Pedersen,Christian, AU - Faurschou,Mikkel, AU - Jacobsen,Søren, Y1 - 2016/05/01/ PY - 2016/03/10/accepted PY - 2016/5/3/entrez PY - 2016/5/3/pubmed PY - 2017/12/8/medline KW - EPIDEMIOLOGY KW - INCIDENCE KW - LUPUS NEPHRITIS KW - SYSTEMIC LUPUS ERYTHEMATOSUS SP - 1335 EP - 9 JF - The Journal of rheumatology JO - J. Rheumatol. VL - 43 IS - 7 N2 - OBJECTIVE: To determine the incidence of systemic lupus erythematosus (SLE) and SLE with concomitant or subsequent lupus nephritis (LN) in Denmark during 1995-2011, using data from the Danish National Patient Registry (NPR). METHODS: To assess the incidence of SLE, we identified all persons aged ≥ 18 years in the NPR with at least 1 International Classification of Diseases, 10th ed (ICD-10) code of SLE and at least 365 days of followup under this diagnosis. Identification of LN cases was based on fulfillment of these criteria and ≥ 1 registration under an ICD-10 code of nephritis concomitantly with or after first SLE registration. RESULTS: The overall annual incidence rate per 100,000 for SLE was 2.35 (95% CI 2.24-2.49); 0.69 (95% CI 0.60-0.78) for men and 3.96 (95% CI 3.75-4.17) for women. For LN, the mean annual incidence rate per 100,000 was estimated to be 0.45 (95% CI 0.38-0.53); 0.20 (95% CI 0.13-0.28) for men and 0.69 (95% CI 0.57-0.83) for women. The differences in SLE incidence rates between sexes decreased by age, and the incidence did not differ between men and women after the age of 60 years for LN. The estimated incidences showed no trends by calendar time. Estimated overall point prevalence (December 31, 2011) per 100,000 was 45.2 (95% CI 43.3-47.4) and 6.4 (95% CI 5.7-7.2) for SLE and LN, respectively. CONCLUSION: Our Danish population-based data showed a stable incidence of SLE and LN. As expected, we found higher incidence rates among women than among men, particularly in younger persons. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/27134247/Incidence_of_Systemic_Lupus_Erythematosus_and_Lupus_Nephritis_in_Denmark:_A_Nationwide_Cohort_Study_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&pmid=27134247 DB - PRIME DP - Unbound Medicine ER -